In addition, multiple MyD88-related pathways were enriched, supporting prior evidence that CDK4/6 inhibitors can reprogram the tumor microenvironment by modulating the IL-33–MyD88 axis, therefore inhibiting suppressive immune cells [100]. Here, CDK4 is linked to neoplasm.